**Core Concept**
Laudanosine is a metabolite produced during the Hofmann elimination, a non-enzymatic degradation process that breaks down certain ester-type neuromuscular blocking agents. This process occurs in plasma and is independent of liver or kidney function.

**Why the Correct Answer is Right**
Atracurium is a non-depolarizing neuromuscular blocking agent that undergoes Hofmann elimination, a process that breaks down the drug into several metabolites, including laudanosine. This degradation process is unique to atracurium and is responsible for the production of laudanosine. Laudanosine is a central nervous system stimulant and has been associated with potential cardiovascular and CNS effects in high concentrations. The Hofmann elimination process is pH-dependent and occurs in plasma, making it a crucial consideration in the clinical use of atracurium.

**Why Each Wrong Option is Incorrect**
**Option A:** Mivacurium is an ester-type neuromuscular blocking agent, but it is primarily metabolized by plasma cholinesterase, not through Hofmann elimination.
**Option B:** Doxacurium is a long-acting non-depolarizing neuromuscular blocking agent, but it does not undergo Hofmann elimination.
**Option C:** Rocuronium is a non-depolarizing neuromuscular blocking agent that is metabolized by the liver and does not undergo Hofmann elimination.

**Clinical Pearl / High-Yield Fact**
The Hofmann elimination of atracurium is pH-dependent, and the degradation rate increases with higher temperatures and lower pH levels. This characteristic is crucial in understanding the clinical pharmacology of atracurium and its potential interactions with other drugs.

**✓ Correct Answer: D. Atracurium. Atracurium is a non-depolarizing neuromuscular blocking agent that undergoes Hofmann elimination, producing laudanosine as a metabolite.**